Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShort-Term Debt repayments
Ratios

China Pharma Holdings (CPHI) Accumulated Depreciation & Amortization (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Accumulated Depreciation & Amortization for 16 consecutive years, with $33.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Depreciation & Amortization rose 1.1% year-over-year to $33.0 million, compared with a TTM value of $33.0 million through Sep 2025, up 1.1%, and an annual FY2024 reading of $32.1 million, up 5.61% over the prior year.
  • Accumulated Depreciation & Amortization was $33.0 million for Q3 2025 at China Pharma Holdings, up from $32.6 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $33.0 million in Q3 2025 and bottomed at $28.2 million in Q4 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $30.8 million, with a median of $31.0 million recorded in 2024.
  • The sharpest move saw Accumulated Depreciation & Amortization grew 0.68% in 2022, then increased 7.21% in 2023.
  • Year by year, Accumulated Depreciation & Amortization stood at $28.2 million in 2021, then increased by 0.68% to $28.4 million in 2022, then grew by 7.21% to $30.4 million in 2023, then grew by 5.61% to $32.1 million in 2024, then increased by 2.72% to $33.0 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for CPHI at $33.0 million in Q3 2025, $32.6 million in Q2 2025, and $32.3 million in Q1 2025.